Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab

Eur J Cancer. 2020 May:131:1-4. doi: 10.1016/j.ejca.2020.02.044. Epub 2020 Apr 2.

Authors

Yuko Watanabe¹, Yukie Yamaguchi², Naoko Takamura¹, Yukitoshi Takahashi³, Michiko Aihara¹

Affiliations

¹ Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
² Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Electronic address: yui1783@yokohama-cu.ac.jp.
³ NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.

PMID: 32248069
DOI: 10.1016/j.ejca.2020.02.044

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Cytokines / blood
Cytokines / immunology
Female
Humans
Melanoma / drug therapy*
Melanoma / immunology
Middle Aged
Mouth Neoplasms / drug therapy*
Mouth Neoplasms / immunology
Nivolumab / adverse effects*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Severity of Illness Index
Stevens-Johnson Syndrome / blood
Stevens-Johnson Syndrome / diagnosis
Stevens-Johnson Syndrome / immunology*
T-Lymphocytes, Regulatory / immunology

Substances

Antineoplastic Agents, Immunological
Cytokines
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab